INTRODUCTION {#sec1-1}
============

Screening is the process of surveying a population with specific markers in order to identify those individuals with a higher risk for a particular disorder. For high risk individuals, a diagnostic test is applied to definitely diagnose the disorder. A successful screening program should be complemented with an accurate diagnostic test to identify those who are truly affected and also with a clear strategy of how to treat the affected individuals.

Over the last four decades, the practice of prenatal screening has evolved from the simple second-trimester maternal serum α-fetoprotein (AFP) test for open neural tube defects (NTDs) to complex combinations of biophysical and biochemical testing for aneuploidy. It continues to evolve with the testing of fetal DNA in the maternal circulation and the development of screening tests for adverse pregnancy outcomes such as pre-eclampsia. Diagnosis of major fetal chromosomal aneuploidies is done by karyotype of fetal cells, obtained through amniocentesis after the 15th week of pregnancy, or chorionic villus sampling (CVS) between the 12^th^ and 14^th^ weeks. There are several financial and ethical implications of how pregnancies with affected fetuses are treated in different countries and these differences are even bigger between Mediterranean countries with different economical, social and cultural status.

BRIEF HISTORICAL OVERVIEW {#sec1-2}
=========================

Screening for fetal aneuploidy in pregnancy began in the 1960-1970s with maternal age as the only available marker. As maternal age increases, the chance of delivering a child with Down syndrome (DS) or other major autosomal trisomies like trisomy 18 (T18; Edwards syndrome) or 13 (T13; Patau syndrome) increases. However, screening with maternal age alone (cut-off \>35years), could detect about 30% of trisomies. The majority of babies with DS are born by women less than 35 years of age.

The first breakthrough in screening for fetal chromosomal abnormalities was done in 1988 with the introduction of a multiple marker screening test, based on a "risk" calculation for each pregnant woman using her age and the concentrations of 3 biochemical markers: human Chorionic Gonadotropin (hCG), AFP, and unconjugated Estriol (uE3) (Triple test) from blood samples in the 2^nd^ trimester of pregnancy \[[@ref1]\]. Such screening has led also to the diagnosis of a large proportion of the other common trisomies, like T18 and T13. In 1992, ultrasound fetal nuchal translucency (NT), by far the single best individual marker, was introduced \[[@ref2]\] and in 1997, a new multiple marker screening test the Combined test, using NT, Fb-hCG and Pregnancy Associated Plasma Protein --A (PAPP-A) was started \[[@ref3]\]. The following years, several complex screening protocols were introduced using both first- and second-trimester markers. [Table 1](#table001){ref-type="table"} \[[@ref4]\] shows the model predicted detection rate (DR) and positive predictive value (PPV) for a 1% or 5% false positive rate (FPR) for the traditional screening strategies described above.

Comparing the first and second trimester screening protocols, 1^st^ trimester's Combined test has better DR than the Triple or Quadruple (Triple+inhibin) test in the 2^nd^ trimester, for 5% FPR. Presently, the Combined test is the preferred multimarker screening protocol in most countries. Protocols combining 1^st^ and 2^nd^ trimester markers, in one step or contingently or using more biochemical or ultrasound markers gave better performance but made the screening more cumbersome, expensive and time consuming.

DNA SCREENING FOR ANEUPLOIDIES {#sec1-3}
==============================

The discovery that there is sufficient cffDNA in maternal plasma, in combination with the next generation sequencing techniques, made the next breakthrough step in screening for DS and other aneuploidies \[[@ref5]\]. In principle, the screening is based on counting a large number of DNA fragments (both maternal and fetal) using massive sequencing, assigning them to a chromosome and quantifying the proportion assigned e.g. to chromosome 21. The results are expressed as a *z* score computed by comparison to an expected proportion for a sample from a euploid fetus. In a recent review and metanalysis \[[@ref6]\], the DR of cffDNA for DS was found 99.4% for 0.1% FPR (results from 148344 tests); for T18, 97.7% for 0,1% (results from 146940 tests); and for T13, 90,6% for 0,1% (results from 134691 tests). The authors concluded that "cffDNA based non-invasive prenatal testing (NIPT) can be diagnostic for fetal sex and rhesus D, but only screening test in aneuploidy".

Concerning the position of cffDNA based NIPT in the established screening strategies, two main approaches have been suggested:

a.  as "primary" testing replacing the conventional screening; and

b.  as "secondary" testing offered after the 1^st^ trimester's Combined test.

In both approaches, a confirmatory invasive prenatal diagnosis by CVS or amniocentesis is necessary for positive results. As a primary test, cffDNA has a much higher screening performance, at least for Down syndrome, than any of the conventional policies summarized in [Table 1](#table001){ref-type="table"}. However, the major concern of this approach is the cost. With the cost for a Down syndrome birth avoided to be almost 10 times higher for cffDNA than the conventional screening \[[@ref7]\], this screening approach could be an unaffordable burden for every health care system. Another consideration is the test failure rate of cffDNA testing. The reported rates for "no-call" results from the commercial companies vary between 2-6%. The main reason for the test failures is the low fraction of fetal DNA in the total amount of free DNA in the maternal circulation. The fetal fraction has to be higher than 10% optimally, and today all the main commercial companies include the fetal fraction in their results' report. As a secondary test, a contingent use of cffDNA test is more cost effective than the use as a primary test. With this approach, conventional 1^st^ trimester combined screening is offered to all women. To those women with a very high risk for all type of aneuploidy (e.g. \>1:50), invasive prenatal diagnosis is offered.

To all other women, the result of the combined test could be used for counseling, giving them the choice of selecting either:

a.  no further action with a result lower than e.g. 1:1000;

b.  proceed with cffDNA testing or

c.  having invasive diagnosis.

An option for this approach is depicted in [Figure 1](#fig001){ref-type="fig"}. (<https://www.nps.org.au/australian-prescriber/articles/non-invasive-prenatal-testing-for-down-syndrome>)

RECENT GUIDELINES FOR SCREENING {#sec1-4}
===============================

In recently published recommendations of the American College of Obstetrician and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine for screening for fetal aneuploidy (<https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Genetics/Cell-free-DNA-Screening-for-Fetal-Aneuploidy>), among others it is mentioned that:

-   A discussion of the risks, benefits, and alternatives of various methods of prenatal screening and diagnostic testing, including the option of no testing, should occur with all patients.

-   Given the performance of conventional screening methods, the limitations of cell-free DNA screening performance, and the limited data on cost-effectiveness in the low-risk obstetric population, conventional screening methods remain the most appropriate choice for first-line screening for most women in the general obstetric population.

-   The cell-free DNA test will screen for only the common trisomies and, if requested, sex chromosome composition.

-   Given the potential for inaccurate results and to understand the type of trisomy for recurrence-risk counseling, a diagnostic test should be recommended for a patient who has a positive cell-free DNA test result.

-   Cell-free DNA screening is not recommended for women with multiple gestations.

-   If a fetal structural anomaly is identified on ultrasound examination, diagnostic testing should be offered rather than cell-free DNA screening.

-   Patients should be counseled that a negative cell-free DNA test result does not ensure an unaffected pregnancy.

THE SITUATION IN MEDITERRANEAN COUNTRIES {#sec1-5}
========================================

Trying to imprint the situation of prenatal screening for chromosomal abnormalities in the different Mediterranean countries, a questionnaire in cooperation with MZ Congressi, was send to the members of Scientific Committee and was uploaded as a survey (<https://docs.google.com/forms/d/e/1FAIpQLSdu6i2dvWbeCbObkGToJV51V8C0A6vA7LYTu0JBPtr4UrL_TQ/viewform>). Unfortunately, a limited number of responses was received (Slovenia, France, Greece, Turkey, Israel and Albania) ([Table 2](#table002){ref-type="table"}).

![Example model for contingent screening for Down syndrome](ejifcc-29-274-g001){#fig001}

###### 

Model predicted DR and PPV for different policies for Down syndrome screening according to FPR

  Policy                                                                FPR=1%   FPR=5%         
  --------------------------------------------------------------------- -------- --------- ---- ---------
  **Second trimester**                                                                          
  Quad                                                                  50       1 in 16   71   1 in 54
  **First trimester**                                                                           
  Combined                                                              72       1 in 12   85   1 in 46
  **Both trimesters**                                                                           
  Serum integrated                                                      58       1 in 14   76   1 in 51
  Integrated                                                            83       1 in 10   92   1 in 42
  Contingent ^[b](#table1-tfn2){ref-type="table-fn"}^                   83       1 in 10   91   1 in 42
  **Improved**                                                                                  
  Combined plus NB                                                      88       1 in 10   94   1 in 41
  First trimester contingent ^[b](#table1-tfn2){ref-type="table-fn"}^   86       1 in 10   90   1 in 43
  Quad plus facial profile                                              83       1 in 10   93   1 in 42
  Combined plus PIGF and AFP                                            77       1 in 11   89   1 in 44

^a^ *At term*

^b^ *First stage cutoff risks 1 in 50 and 1 in 2000 at term*

###### 

Brief summary of the responses received from some Mediterranean countries

  Question                             Slovenia   France    Greece    Turkey    Israel    Albania
  ------------------------------------ ---------- --------- --------- --------- --------- ---------
  Is screening regulated by low?       Yes        Yes       No        Yes       Yes       No
  Is screening compulsory?             No         No        No        No        No        No
  Is screening reimbursed?             Yes        Yes       Yes       Yes       Yes       No
  **Screening strategies**                                                                
  l ^st^ trimester only                No         Yes       No        No        No        No
  l ^st^ or 2^nd^ trimester            Yes        **-**     Yes       Yes       Yes       Yes
  cfDNA testing                        Yes        Yes       Yes       Yes       Yes       Yes
  cfDNA testing reimbursed?            No         No        No        No        No        No
  Primary or secondary                 Sec                  Sec       Sec                 
  Cost of cfDNA testing (€)            \~450                350-650   400-600   \-        600-800
  **Invasive cytogenetic diagnosis**                                                      
  Woman's age only                     Yes        No        Yes       Yes       Yes       Yes
  Screening results                    Yes        Yes       Yes       Yes       Yes       Yes
  Other indications (US, family)       Yes        Yes       Yes       Yes       Yes       Yes
  US monitoring                        Yes        Yes (3)   Yes (3)   Yes       Yes (3)   Yes
